Landscapes / Targets
CD22
10 drugs act on CD22, in 11 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs10
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Monoclonal antibody |
Pfizer · Public PFE |
Approved | 21 May 2033Phase 2 trial completes | ||
| How it works | An antibody | ||||
| Next date | 21 May 2033 · Phase 2 trial completes | ||||
| Also tested for | ACUTE LYMPHOBLASTIC LEUKEMIA | ||||
| Open drug page | |||||
— |
Phase 1/2 | 31 Dec 2026Phase 1/2 trial completes | |||
| Next date | 31 Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | B-ALL | ||||
| Open drug page | |||||
— |
Phase 1/2 | 14 Mar 2027Phase 1/2 trial completes | |||
| Next date | 14 Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL and 5 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Aug 2027Phase 1/2 trial completes | |||
| Next date | Aug 2027 · Phase 1/2 trial completes | ||||
| Also tested for | B-cell Non-Hodgkin Lymphoma (B-NHL) | ||||
| Open drug page | |||||
— |
AstraZeneca · Public AZN |
Phase 1/2 | 4 Jul 2028Phase 1/2 trial completes | ||
| Next date | 4 Jul 2028 · Phase 1/2 trial completes | ||||
| Also tested for | B-cell Acute Lymphoblastic Leukemia (B-ALL), B-cell Non-Hodgkin Lymphoma | ||||
| Open drug page | |||||
— |
Umoja Biopharma · Private |
Phase 1/2 | Aug 2031Phase 1/2 trial completes | ||
| Next date | Aug 2031 · Phase 1/2 trial completes | ||||
| Also tested for | Lymphoma, B Cell, Lymphoma Non-Hodgkin and 5 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | — | |||
| Also tested for | B-cell Non-Hodgkin's Lymphoma | ||||
| Open drug page | |||||
— |
Phase 1/2 | — | |||
| Also tested for | B-cell Acute Lymphoblastic Leukemia | ||||
| Open drug page | |||||
— |
Phase 1 | 30 Mar 2027Phase 1 trial completes | |||
| Next date | 30 Mar 2027 · Phase 1 trial completes | ||||
| Also tested for | 19 and 22+ B Cell Hematologic Tumors, 19 and 20+ B Cell Hematologic Tumors | ||||
| Open drug page | |||||
— |
Regeneron · Public REGN |
Phase 1 | 16 Feb 2029Phase 1 trial completes | ||
| Next date | 16 Feb 2029 · Phase 1 trial completes | ||||
| Also tested for | B-cell Non-Hodgkins Lymphoma (B-NHL) | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 10 of 10 drugs. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026